Viasat identified as victim in Chinese Salt Typhoon cyberespionage, Bloomberg News reports
(Reuters) -Viasat Inc has been identified as a victim of the Chinese-linked Salt Typhoon cyberespionage operation during last year's presidential campaign, Bloomberg News reported on Tuesday.
The breach at the satellite communications firm was discovered earlier this year and Viasat has been working with the government in the aftermath, the report said, citing people familiar with the matter.
Viasat did not immediately respond to a Reuters request for comment on the report.
U.S. officials have previously alleged that hackers targeted telecom companies such as Verizon, AT&T, Lumen, and others, stealing telephone audio intercepts along with a significant amount of call record data.
In December, the officials added a ninth unnamed telecom company to the list of entities compromised by the Salt Typhoon hackers and said that the Chinese operatives gained access to networks with broad and full access, enabling them to "geolocate millions of individuals, to record phone calls at will".
Targets of Salt Typhoon reportedly included officials connected to the presidential campaigns of both Democrat Kamala Harris and Republican Donald Trump.
Chinese officials have previously dismissed the allegations as disinformation, asserting that Beijing "firmly opposes and combats cyber attacks and cyber theft in all forms".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Why KULR Technology Stock Is Plummeting Today
After the market closed last Friday, KULR announced that it will carry out a reverse stock split. KULR will implement an 8-for-1 reverse stock split on June 23. The reverse split will help KULR keep trading on its current exchange, but some investors are seeing negative signs in the move. 10 stocks we like better than KULR Technology Group › KULR Technology (NYSEMKT: KULR) stock is getting hit with huge selling action in Monday's trading. The company's share price was down 21.3% as of 3 p.m. ET, despite the S&P 500 (SNPINDEX: ^GSPC) being up 0.9% at the same point in the day's trading. KULR is seeing a big valuation pullback today following news that the company will carry out a reverse stock split. The new structure for the stock won't do anything to alter the fundamentals of the business, but investors are dumping shares ahead of the 8-for-1 reverse split that will take effect on June 23. After surging late in 2024's trading, KULR stock has seen big sell-offs this year. The company's share price is down roughly 74.5% year to date. As a result of the big valuation pullback, KULR's share price is currently below the $1 threshold necessary to continue trading on the NYSE-American Market. By announcing the reverse stock split before its shares had been trading below the threshold for a significant amount of time, KULR may also be able to avoid new rules from the New York Stock Exchange approved earlier this year that make it more difficult to use reverse splits to remain in compliance. KULR's reverse stock split will take effect next Monday and will result in the equivalent of eight existing shares being combined into one new share. The move will have the effect of boosting the company's share price, but it won't alter the fundamentals of the business. Continuing to trade on the NYSE-American Market exchange is probably a good thing for KULR over the long term because it will continue to make the stock easily available for a wide range of investors. On the other hand, it's not hard to see why some investors are reacting negatively to the reverse stock-split news. Reverse splits often occur because a company and its stock are struggling, and they can also limit some of the potential for explosive short-term gains that some investors may be seeking with penny stocks. Before you buy stock in KULR Technology Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and KULR Technology Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why KULR Technology Stock Is Plummeting Today was originally published by The Motley Fool
Yahoo
24 minutes ago
- Yahoo
Richard Sherman charged with DUI from February 2024 arrest
Former NFL All-Pro cornerback Richard Sherman was formally charged with DUI in connection to his February 2024 arrest, according to an ESPN report. Sherman was arrested on suspicion of driving under the influence and booked into the King County Correctional Facility in Seattle in the early morning of Feb. 24, 2024, according to jail records previously obtained by USA TODAY Sports. Advertisement Citing the King County Prosecuting Attorney's Office, ESPN reported officials had been awaiting blood-test results from the Washington State Patrol Crime Lab taken the night of the arrest. It was received June 16, which showed Sherman had a blood alcohol level around 0.11, higher than the state's legal limit of 0.08. "Thursday Night Football" analyst Richard Sherman talks during a pregame show before a game between the Philadelphia Eagles and Washington Commanders at Lincoln Financial Field on Nov. 14, 2024. Richard Sherman DUI arrest details According to documents, Sherman was pulled over just before 2 a.m. local time after a Washington State Patrol officer reported he was driving above the speed limit and veering on a highway in Renton, about 12 miles southeast of Seattle. Officers reportedly noticed an "odor of intoxicants" from Sherman's breath. He allegedly refused a breath test at the scene and was taken to a hospital for a blood draw before he was booked. Advertisement The DUI charge is a gross misdemeanor charge, ESPN said, and it includes an enhancement for refusing a breath test. Sherman will be arraigned June 30. Sherman was previously had been arrested for driving under the influence following an incident in July 2021 in Redmond, Washington. Police said Sherman crashed his SUV in a construction zone and tried to break into his in-laws' home. He pleaded guilty to two misdemeanor charges of first-degree negligent driving and second-degree criminal trespass related to the incident in a plea bargain in March 2022. A five-time Pro Bowler, Sherman played 11 seasons in the NFL. Seven of those seasons were spent with the Seattle Seahawks, as he was part of the famed "Legion of Boom" unit that anchored one of the top defenses in the league. He was a major contributor on the 2013 team that won Super Bowl 48. He currently serves as an analyst for Prime Video's "Thursday Night Football." Contributing: Cydney Henderson This article originally appeared on USA TODAY: Richard Sherman charged with DUI from February 2024 arrest
Yahoo
25 minutes ago
- Yahoo
Biomea Fusion Announces Pricing of Public Offering of Securities
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea') (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire eighteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.9999. All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million, excluding any exercise of the underwriters' option to purchase additional shares and/or warrants. The offering is expected to close on June 20, 2025, subject to the satisfaction of customary closing conditions. Jefferies is acting as sole book-running manager for the offering The shares of common stock, pre-funded warrants and common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Biomea pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267884), that was previously filed with the U.S. Securities and Exchange Commission ('SEC') on October 14, 2022 and declared effective on October 24, 2022. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 17, 2025 and is available for free on the SEC's website located at The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@ or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. Visit us at and follow us on LinkedIn, X and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea's beliefs and expectations regarding the anticipated public offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the proposed offering, and Biomea's research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the public offering on the anticipated terms, or at all, market conditions and statements regarding the expected gross proceeds of the offering, timing of closing of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities and Biomea's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Biomea's most recent annual report on Form 10-K filed on March 31, 2025 and subsequent quarterly reports on Form 10-Q, filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. Any forward-looking statements contained in this press release represent Biomea's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Contact:Meichiel Jennifer WeissSr. Director, Investor Relations and Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
